Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retention of Young Thai Men Who Have Sex with Men at Risk of HIV Using Event-Driven PrEP
TCTR20211216006Active, not recruiting
- Sponsor
- Chulalongkorn University
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by Chulalongkorn University. Primary endpoint: Retention in event-driven PrEP care. Started Aug 2020; status: active, not recruiting.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20211216006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211216006.